Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia

Documenti analoghi

• Correction to “Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia”
  Pubblicazione: (2026)
• Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme
  di: Chin Hang Yiu, et al.
  Pubblicazione: (2026)
• Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs
  di: Miquel Serra‐Burriel, et al.
  Pubblicazione: (2026)
• Comparative Effectiveness of First‐Line Pembrolizumab vs. Chemotherapy in aNSCLC : A Norwegian Population‐Based Cohort Study
  di: Simon Boge Brant, et al.
  Pubblicazione: (2025)
• Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
  di: Terry Cheuk‐Fung Yip, et al.
  Pubblicazione: (2025)